Emergent BioSolutions (EBS) Total Debt: 2010-2025
Historic Total Debt for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $663.1 million.
- Emergent BioSolutions' Total Debt rose 0.20% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 0.20%. This contributed to the annual value of $663.7 million for FY2024, which is 48.65% up from last year.
- Emergent BioSolutions' Total Debt amounted to $663.1 million in Q3 2025, which was down 0.70% from $667.8 million recorded in Q2 2025.
- Over the past 5 years, Emergent BioSolutions' Total Debt peaked at $1.0 billion during Q3 2022, and registered a low of $446.5 million during Q4 2023.
- Over the past 3 years, Emergent BioSolutions' median Total Debt value was $448.2 million (recorded in 2023), while the average stood at $546.0 million.
- In the last 5 years, Emergent BioSolutions' Total Debt plummeted by 56.57% in 2023 and then skyrocketed by 49.40% in 2025.
- Quarterly analysis of 5 years shows Emergent BioSolutions' Total Debt stood at $809.4 million in 2021, then crashed by 44.59% to $448.5 million in 2022, then fell by 0.45% to $446.5 million in 2023, then spiked by 48.65% to $663.7 million in 2024, then increased by 0.20% to $663.1 million in 2025.
- Its last three reported values are $663.1 million in Q3 2025, $667.8 million for Q2 2025, and $665.7 million during Q1 2025.